Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert Paul Hasserjian, M.D.

Co-Author

This page shows the publications co-authored by Robert Hasserjian and Valentina Nardi.
Connection Strength

5.351
  1. Bedside to Bench and Back: Identifying a New Clinically Relevant Driver in Pediatric Acute Myeloid Leukemia. Blood Cancer Discov. 2022 Feb 16.
    View in: PubMed
    Score: 0.987
  2. Premalignant Clonal Hematopoietic Proliferations. Am J Clin Pathol. 2019 08 01; 152(3):347-358.
    View in: PubMed
    Score: 0.827
  3. Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Surg Pathol Clin. 2016 Mar; 9(1):143-63.
    View in: PubMed
    Score: 0.653
  4. Routine conventional karyotyping of lymphoma staging bone marrow samples does not contribute clinically relevant information. Am J Hematol. 2015 Jun; 90(6):529-33.
    View in: PubMed
    Score: 0.616
  5. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol. 2012 Jul 01; 30(19):2340-7.
    View in: PubMed
    Score: 0.502
  6. An unusual lymphoma involving the GI tract and bone marrow. Am J Hematol. 2022 Mar 07.
    View in: PubMed
    Score: 0.248
  7. Myelodysplastic syndromes with no somatic mutations detected by next-generation sequencing display similar features to myelodysplastic syndromes with detectable mutations. Am J Hematol. 2021 11 01; 96(11):E420-E423.
    View in: PubMed
    Score: 0.239
  8. JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology. Am J Surg Pathol. 2021 07 01; 45(7):895-904.
    View in: PubMed
    Score: 0.236
  9. Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. Hum Pathol. 2019 04; 86:1-11.
    View in: PubMed
    Score: 0.199
  10. Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Mol Diagn. 2015 Nov; 17(6):661-8.
    View in: PubMed
    Score: 0.158
  11. High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Mod Pathol. 2015 Apr; 28(4):552-63.
    View in: PubMed
    Score: 0.149
  12. TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes. Cancers (Basel). 2021 Nov 02; 13(21).
    View in: PubMed
    Score: 0.060
  13. Myeloid/lymphoid neoplasms with FLT3 rearrangement. Mod Pathol. 2021 09; 34(9):1673-1685.
    View in: PubMed
    Score: 0.059
  14. Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma. Oncologist. 2021 07; 26(7):e1263-e1272.
    View in: PubMed
    Score: 0.058
  15. Genomic alterations in patients with somatic loss of the Y chromosome as the sole cytogenetic finding in bone marrow cells. Haematologica. 2021 02 01; 106(2):555-564.
    View in: PubMed
    Score: 0.057
  16. Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A-YAP1 and VIM-KMT2A fusions. Mod Pathol. 2020 11; 33(11):2307-2317.
    View in: PubMed
    Score: 0.055
  17. Pan-Cancer Landscape Analysis Reveals Recurrent KMT2A-MAML2 Gene Fusion in Aggressive Histologic Subtypes of Thymoma. JCO Precis Oncol. 2020; 4.
    View in: PubMed
    Score: 0.054
  18. Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Mod Pathol. 2019 09; 32(9):1373-1385.
    View in: PubMed
    Score: 0.051
  19. Therapy-Related Erythroleukemia in a Man With Metastatic Ewing Sarcoma: A Clinical Role for Advanced Molecular Diagnostics. JCO Precis Oncol. 2018 Nov; 2:1-6.
    View in: PubMed
    Score: 0.049
  20. High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018 06 21; 131(25):2816-2825.
    View in: PubMed
    Score: 0.047
  21. Combined Targeted Therapy for BRAF-Mutant, Treatment-Related Acute Myeloid Leukemia. JCO Precis Oncol. 2017 Nov; 1:1-7.
    View in: PubMed
    Score: 0.046
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.